The integrity of your research depends on the quality of your peptides \u2014 and immune studies require nothing less than perfection. Impurities can skew cytokine assays, mask therapeutic potential, or worse, put years of scientific work at risk. CellPeptides delivers pharma-grade T\u03b11 that researchers can confidently use to push their studies forward.<\/p>\n
Our Thymosin Alpha-1 is:<\/p>\n
CellPeptides ships globally and quickly. Packages are insured and have tracking codes. Our customer support team is always on the clock to answer your questions about ordering or peptide research. Your search for a reliable research and scientific company for all your peptide sourcing? It ends with CellPeptides \u2014 so you can start your research right now.<\/p>\n
Thymosin Alpha-1 isn\u2019t another immune booster. This 28-amino acid peptide builds a smarter, more effective immune response \u2014 and in four different ways.<\/p>\n
T\u03b11 activates dendritic cells by acting on toll-like receptors (especially TLR9 and TLR2), which scout the body for threats. That improves pathogen detection and sets the body up for a more effective response.<\/p>\n
It helps to make sure that T-cells mature on track, pushes the immune system toward a Th1-biased response that makes it fight threats (cancer, viruses, bacteria\u2026) faster and more efficiently, and it brings the immune system back into balance after a period of intense stress. Its success in restoring immune homeostasis means it\u2019s no surprise that Thymosin Alpha-1 is a powerful immune support system after chemotherapy and for patients with chronic viral infections.<\/p>\n
Thymosin Alpha-1 is clinically used to support patients with cancer and chronic hepatitis in many parts of the world \u2014 especially in Europe. The peptide has exciting research potential far beyond those established applications, however.<\/p>\n
Research into the potential applications of Thymosin Alpha-1 has been emerging since the peptide was first described in the 1970s \u2014 when it became the first peptide from Thymosin Fraction 5 to be fully sequenced and synthesized. Thymosin Alpha-1 is, primarily, an immunomodulator. Most research has focused on that area.<\/p>\n
Curious what else research into the practical benefits of Thymosin Alpha-1 has touched on? This section is for you \u2014 and you\u2019ll find links to further reading below to continue your investigations.<\/p>\n
Chemotherapy is life-saving, but it destroys the immune system along with cancer cells \u2014 and rebuilding it takes time, time during which patients are uniquely vulnerable. Thymosin Alpha-1 speeds this difficult process up. That\u2019s not all it does, though. Studies have also discovered that\u00a0 Thymosin Alpha-1 makes cancer treatment more effective by putting the body in a stronger position to fight residual cancer cells. [1<\/a>]\n It does not, to be clear, have potential as a stand-alone treatment for cancer. As Thymosin Alpha-1 builds a stronger body, a more resilient body, after treatment, however, research points to improved survival rates and a faster return to health.<\/p>\n We already mentioned that Thymosin Alpha-1 doesn\u2019t simply stimulate the immune system, but actually regulates it \u2014 which means it also has interesting applications for autoimmune diseases, as contradictory as this looks to be at first glance. Early research (and this area of investigation is<\/em> still in its infancy!) hints at the potential to balance the Th1\/Th2 immune axis and boost the production of regulatory T-cells. [2<\/a>]\n So far, studies have looked at the possibility that Thymosin Alpha-1 might restore that Th1\/Th2 balance in rheumatoid arthritis [3<\/a>] and reduce multiple sclerosis flareups [4<\/a>].<\/p>\n The thymus, from which Thymosin Alpha-1 was isolated, gradually shrinks with age \u2014 and with that shrinkage, immune function also declines. [5<\/a>] What if Thymosin Alpha-1 could slow that decline? Research determined to find the answer to that question is in progress. It may open the door for better resilience in the face of pathogens with age, and this makes T\u03b11 a worthwhile peptide for researchers studying longevity.<\/p>\n Sepsis is a life-threatening reaction to systemic infections that leads to \u201cimmunoparalysis\u201d \u2014 that is, it causes a deep state of immunosuppression. It\u2019s immediately apparent how a powerful immune regulator like Thymosin Alpha-1 might be able to come in and fix that dysregulation. Indeed, research has already looked at this [6<\/a>]. While there\u2019s more work to be done in that area, results show a reduced risk of death from sepsis.<\/p>\n Beyond the areas where Thymosin Alpha-1 has already been widely studied, glimpses of other potential benefits are also emerging. One of them is in the reduction of viral loads in COVID-19 patients \u2014 and<\/em> reduced fatigue among people with \u201clong COVID.\u201d [7<\/a>] Another is possible anti-depressive effects, specifically for people with weak immune systems [8<\/a>].<\/p>\n The clinical studies conducted to date show that Thymosin Alpha-1 has a lot of promise, but the research continues. The potential of T\u03b11 is most interesting to researchers studying adjunct therapy for cancer, to virologists looking at chronic infection management, to autoimmune investigators hoping to discover alternatives to blunt-force immunosuppression, and to longevity researchers.<\/p>\n T\u03b11 is a smart answer to the broad-acting immune boosters and suppressants \u2014 a more targeted way to signal the body to bring itself back into balance. The potential? Let\u2019s just say that existing research has likely scratched no more than the surface. What direction will your studies take?<\/p>\n Thanks to an impressive body of research, dosing protocols for Thymosin Alpha-1 are already well-established \u2014 although the dose depends on the goal of the research.<\/p>\n Most commonly, researchers recommend a starting dose of 0.1 to 0.5 mg per dose. This dose assesses tolerance in your model and establishes a baseline immune response \u2014 even microgram variations can and do impact effects, so gradual upward titration is recommended.<\/p>\n The standard research dosing is 1 to 3 mg per dose. That is, 1 mg for chronic low-grade inflammation studies, 1.5 to 2 mg for oncology research, and 3 mg for acute infection. Daily dosing is used for acute challenges, while twice-weekly dosing is more common for chronic conditions.<\/p>\n To reconstitute:<\/p>\n Follow lab protocols; use alcohol on vial tops and administration sites and low-dead-space syringes for \u22640.5 mg doses. Avoid with concurrent immunosuppressants such as cyclosporine. Keep careful lab logs.<\/p>\n What are the main benefits of Thymosin Alpha-1?<\/strong><\/p>\n Above all, it\u2019s a powerful immunomodulator. Well-documented effects of Thymosin Alpha-1 include improved response to checkpoint inhibitors in cancer treatment, infection defense, better immune balance overall, and better defense against the age-related decline seen in the immune system.<\/p>\n What are the side effects of Thymosin Alpha-1?<\/strong><\/p>\n Participants in most studies tolerate Thymosin Alpha-1 well, but passing fatigue and redness around the injection site are possible. No serious side effects have been documented, but contraindications exist and should be kept in mind.<\/p>\n Is Thymosin Alpha-1 a natural peptide?<\/strong><\/p>\n It\u2019s a 28-amino acid peptide that was initially isolated from the thymus. The synthetic version that is used in research settings (and available to buy from CellPeptides) is identical to the natural peptide \u2014 a long way to say \u201cyes.\u201d<\/p>\n What happens when you have too little Thymosin?<\/strong><\/p>\n Deficiencies in Thymosin Alpha-1 weaken the immune system. They are associated with infections, low T-cell counts, chronic inflammation, and poor response to vaccines.<\/p>\n Can Thymosin Alpha-1 be taken orally?<\/strong><\/p>\n No, because stomach acid destroys Thymosin Alpha-1. Research uses subQ, intranasal, or IV delivery.<\/p>\n DISCLAIMER:<\/strong><\/em><\/p>\n Our peptides can be used solely for in vitro experiments and cannot be:<\/em><\/p>\n Tymozyna alfa-1<\/strong> jest przede wszystkim immunomodulator<\/strong>. Nie tyle \u201cwzmacnia\u201d uk\u0142ad odporno\u015bciowy, ile przywraca i normalizuje jego naturalne funkcjonowanie \u2013 tymozyna alfa-1 stymuluje uk\u0142ad odporno\u015bciowy, gdy potrzebuje on wsparcia, i wycisza go, gdy pracuje ponad miar\u0119. Ten peptyd zosta\u0142 wyizolowany z grasicy, gruczo\u0142u odpowiedzialnego za produkcj\u0119 i dojrzewanie limfocyt\u00f3w T.<\/p>\n Jego syntetyczna posta\u0107 jest szeroko badana i stosowana klinicznie w ponad 35 krajach \u2013 w celu odbudowy uk\u0142adu odporno\u015bciowego os\u0142abionego przez nowotwory lub przewlek\u0142e zapalenie w\u0105troby, a tak\u017ce w leczeniu chor\u00f3b autoimmunologicznych, takich jak stwardnienie rozsiane i reumatoidalne zapalenie staw\u00f3w. Nowe badania wskazuj\u0105 nawet na inne zastosowanie tymozyny alfa-1 \u2013 budowanie silniejszego uk\u0142adu odporno\u015bciowego w obliczu spadku odporno\u015bci zwi\u0105zanego z wiekiem.<\/p>\n Dla badaczy zajmuj\u0105cych si\u0119 immunoterapi\u0105 nowotwor\u00f3w (piersi, p\u0142uc, w\u0105troby, czerniakiem), przewlek\u0142ymi infekcjami, chorobami autoimmunologicznymi i d\u0142ugowieczno\u015bci\u0105.<\/p>","protected":false},"featured_media":1042,"template":"","meta":{"_acf_changed":false,"ub_ctt_via":""},"product_brand":[],"product_cat":[52,46,54],"product_tag":[],"class_list":["post-910","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory-response-research-peptides","product_cat-peptides-for-longevity-research","product_cat-peptides-for-tissue-healing-research","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\nThymosin Alpha-1 Research and Autoimmune Diseases<\/h3>\n
Immune Aging and Thymosin Alpha-1 in Longevity Research<\/h3>\n
Thymosin Alpha-1 in Sepsis Research<\/h3>\n
Exciting Future Applications<\/h3>\n
Who Might Consider Thymosin Alpha-1?<\/h2>\n
Common Dosing Protocols for Thymosin Alpha-1 In-vitro Research Setting<\/h2>\n
\n
FAQs<\/h2>\n
\n
Scientific References<\/em><\/h3>\n
\n